header logo image

For sale: Long-acting PhIII GLP-1 diabetes drug that’s way behind rivals, now spurned by Sanofi – Endpoints News

December 12th, 2019 4:52 pm

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that hes pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now its pulling out entirely. As part of the pullback, its dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history, Hudson said on a call with reporters, according to the Wall Street Journal. As tough a choice as that is, were making that choice.

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read this article:
For sale: Long-acting PhIII GLP-1 diabetes drug that's way behind rivals, now spurned by Sanofi - Endpoints News

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick